Gideon Bollag

Dr. Bollag previously served as Plexxikon’s chief executive officer. Under his leadership, the team developed two FDA-approved drugs, Zelboraf® for metastatic melanoma and Turalio® for tenosynovial giant cell tumor (TGCT). Dr. Bollag was also a member of the founding scientific team at Onyx Pharmaceuticals, where he oversaw the discovery of Nexavar® approved to treat renal cell and liver cancer, and Ibrance® for advanced breast cancer. He serves on the external advisory board of the National Cancer Institute’s RAS initiative and on the scientific advisory board at Ambagon Therapeutics. Dr. Bollag received his PhD in biochemistry from the University of California, Berkeley.